Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science

Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r

Successful initiation of the Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Comp

Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expect

US stocks mixed, Nasdaq up 0.39% as Dow down 0.03%. Target Corp beats earnings, oil down 2.4% and mo

Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204

Dow Jones falls 500 points, S&P drops 1.29%, NASDAQ down 1.79%. Energy shares rise 1.2%, tech st

Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion

Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-

Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clin

CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic c

Silexion Therapeutics Corp (NASDAQ: SLXN - Get Free Report) was down 0.9% during mid-day trading on

Significant regulatory milestone marks advancement into clinical-stage development of next-generatio

Significant regulatory milestone marks advancement into clinical-stage development of next-generatio

Throughout the year, the Company reported significant positive preclinical findings for SIL204 acros

Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial i

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexi

Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advanci

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 202

New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhib